News

May 20 2010

B.C. Signs Agreement with Japanese Company to Beat Cancer

OSAKA, JPN – The BC Cancer Agency and the Vancouver Protate Centre announced a formal agreement with Japan-based Takeda Pharmaceutical Co. Ltd. for new drug treatments to fight breast, ovarian and prostate cancers.The agreement is expected to bring almost $1 million in new cancer research funding to British Columbia.“We have been able to attract this investment in cancer research to British Columbia because of the unique integration of world-class care and research being done by the BC Cancer Agency and the Vancouver Prostate Centre,” said Premier Gordon Campbell.

Read more
Apr 30 2010

Queensland Government funds international drug discovery alliance

An international project using exotic wildlife to find cures for prostate cancer and other fatal diseases has received major Queensland Government funding.Queensland Premier Anna Bligh has today announced that $1.53 million Smart Futures Fund grant to support a new $6.2 million Queensland-British Columbia Drug Discovery Alliance between Griffith University’s Eskitis Institute, the Australian Prostate Cancer Research Centre, and two British Columbia research centres -- the Centre for Drug Research and Development and the Vancouver Prostate Centre.The breakthrough project’s ultimate goal is t

Read more
Mar 25 2010

Le Vancouver Prostate Centre et Astrazeneca Prolongent Leur Entente de Partenariat de Recherche

VANCOUVER, COLOMBIE-BRITANNIQUE – Le Vancouver Prostate Centre a annoncé la prolongation de son partenariat avec AstraZeneca, ce qui lui permettra de recevoir un montant de 700 000 $ sur deux ans pour financer la recherche sur le cancer de la prostate réfractaire au traitement.L’objectif de cette recherche, dont la coordination est assurée par le Vancouver Prostate Centre, un centre d’excellence quant à la commercialisation et à la recherche, est d’évaluer les petites molécules découvertes par AstraZeneca qui ciblent les récepteurs des androgènes et le cycle de croissance cellulaire, afin d

Read more
Mar 04 2010

Astrazeneca Invests $2.1 million in support of Cancer Resarch in BC

Investment recognizes world class oncology research and development expertise at BC Cancer Agency and Vancouver Prostate Centre.MISSISSAUGA, ONTARIO – AstraZeneca Canada is pleased to announce a $500,000 investment to support oncology research and development at the BC Cancer Agency (BCCA).

Read more
Jan 25 2010

Vancouver Prostate Centre and Astrazeneca Extend Collaborative Research Agreement

VANCOUVER, BRITISH COLUMBIA – The Vancouver Prostate Centre announced today an extended collaboration with AstraZeneca that sees the Vancouver Prostate Centre receive $700,000 over two years towards research that targets treatment-resistant prostate cancer.The research, which is being coordinated through the Vancouver Prostate Centre ― a Centre of Excellence for Commercialization and Research ― evaluates AstraZeneca's androgen receptor-targeting small molecules, as well as, molecules that target cell cycle growth to slow, or stop, tumour proliferation in prostate cancer.Specifically this re

Read more
Dec 03 2009

Pfizer and B.C. Launch $9m Collaboration to Tackle Cancer

VANCOUVER – Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer.

Read more
Nov 24 2009

MDRNA Expands RNAi Bladder Cancer Program

Decision to Expand Based Upon Promising Pre-Clinical ResultsBOTHELL, WA – (MARKETWIRE via COMTEX) – MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the extension and expansion of its collaboration with the Vancouver Prostate Centre (VPC), covering the discovery and development of RNAi-based therapeutics for the treatment of bladder cancer.

Read more
Nov 04 2009

OGX-427 in Clinical Trial for Bladder Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer.In preclinical studies conducted by the Vancouver Prostate Centre, OGX-427 had single-agent activity in multiple cancers. In preclinical models of bladder cancer, the investigators observed that bladder cancer tumors were significantly smaller six weeks after OGX-427 administration compared to the control group.View full Press Release

Read more
Nov 02 2009

Prostate Centre-Discovered Cancer Drugs Show Promise

Two cancer drugs discovered at Vancouver Prostate Centre show promise in treating prostate and other cancersDuring the recent American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, promising results from two drugs (OGX-011 and OGX-427) discovered at the Vancouver Prostate Centre were presented in two separate oral presentations, an unprecedented milestone for the Centre.The Vancouver Prostate Centre is a UBC and CECR National Centre of Excellence whose integrated team-science approach and state of the art infrastructure facilitate rapid bench-to-bedside translation

Read more

Pages

News